Navigation Links
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Date:4/15/2008

ipilimumab administered on the first day of the

28-day cycle for up to four cycles. Ipilimumab dosing initially ranged

from 0.5 mg/kg to 3 mg/kg. Additional patients are now being treated

with higher doses (5 mg/kg and 10 mg/kg) of ipilimumab. The treatment

combination was generally well-tolerated. Adverse events associated

with ipilimumab treatment are consistent with data previously reported

from this study and from other clinical trials of ipilimumab.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein relating to the interim data from ongoing ipilimumab combination Phase 1 studies may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014   ... of advanced cancer genome analysis and testing services, ... discovering and developing highly selective kinase inhibitors for ... genomic study of malignant mixed Mullerian tumors (MMMT), ... reproductive system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/20/2014)... Traditionally dentists have advised their patients against ... Dentistry is re-visiting that advice and changing his stance ... and wine have on oral health. “There’s good news and ... may be beneficial in protecting against gum disease, and red ... on coffee was from the September 2014 issue of ...
(Date:9/20/2014)... 20, 2014 QueenBeeTickets.com is ready to ... tour performances. She will visit many cities in North ... the 16th of April. , Click Here ... tickets at QueenBeeTickets.com. , The star’s fans are not ... their favorite young singer in a live performance. Ariana ...
(Date:9/20/2014)... “Motherhood is a wonderful gift and a huge responsibility,” says ... , “We know that you want to care for your ... to do as well.” , The article explains to new ... Family Physicians who practice obstetrics while pregnant, during delivery, and ... learn more about Community Health Center of Snohomish County and ...
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic ... patients with prescription drug coverage, may now be infiltrating ... from the Department of Health and Human Services ... prohibit suppliers from offering side-payments to increase sales of ... The report highlights that two recent surveys, including one ...
(Date:9/19/2014)... September 19, 2014 On September 16, ... the Platinum PR and Top Places to Work in ... York City. Camino received honorable mentions in two categories ... for its work elevating Latina voices in the media. ... and be a part of its efforts to improve ...
Breaking Medicine News(10 mins):Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2
... transform your medical center, and recharge your organization? A ... Future," may hold the key to revitalization. It will be ... President and CEO Nancy Schlichting will share her radical, but ... wisdom of her top executives in an interactive session on ...
... Illinois have identified a potential drug target for the ... in the membrane of neurons and other cells. ... receptor, sparking increased activity in the affected neurons, eventually ... findings appear in the FASEB Journal . ...
... Columbia University,s Mailman School of Public Health today announced ... the Frank A. Calderone Prize to Susan P. ... close to five decades has been instrumental in bringing the ... public policy. Professor Baker, an epidemiologist and licensed ...
... ... a percentage of fees from new clients to World Vision Canada on April 26th and ... (PRWEB) ... , is hoping to raise thousands of dollars for vulnerable people around the world while ...
... Supporting healthy ... ... in the care for mothers and infants, Brigham and Women’s Hospital (BWH) announces the launch ... healthy moms, pregnancies and babies. The Stork Fund will raise funds for clinical care, ...
... ... Dr. Oscar Ramirez, facial implants counteract this phenomenon and offer hope to those with facial ... (PRWEB) April ... belief that superficial matters such as beauty pale in comparison with deeper values such as ...
Cached Medicine News:Health News:Henry Ford Health System goes radical: Creating the hospital of the future 2Health News:Team finds promising new drug target for Alzheimer's disease 2Health News:Team finds promising new drug target for Alzheimer's disease 3Health News:Highest prize in public health -- the Frank A. Calderone Prize -- to Susan Baker, pioneer 2Health News:Tax Return Appointment Fees to be Donated to Charity by Tax Team Canada 2Health News:Brigham and Women's Hospital Launches Stork Fund 2Health News:Brigham and Women's Hospital Launches Stork Fund 3Health News:Boca Raton Plastic Surgeon's New Facial Implants Counteract Facial Aging 2Health News:Boca Raton Plastic Surgeon's New Facial Implants Counteract Facial Aging 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: